A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors 72-year-old patient with urothelial bladder cancer (Lynch syndrome) who had previously received ...
Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors: 72-year-old patient with urothelial bladder cancer who had previously received gemcitabine plus ...
Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy ...
AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...
At ESMO, oncologists got their first look at the results of the EV-302/KEYNOTE-A39 trial of MSD’s PD-1 inhibitor Keytruda (pembrolizumab ... with metastatic bladder cancer,” said Dr Apolo ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...